BioSpace News Archive

Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.

The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.

Investors are still hungry for cutting-edge biotech companies that can make a difference in people’s lives with the hope of a big return on investment. Here’s a look at two recent big funding rounds.

CPhI Japan, the first large pharma event to trade in 2021, played host to 7214 attendees at the exhibition and a further 7204 virtual users from across the globe.

Alpha-9 Theranostics announced the closing of an $11 million Series A financing today, while Engage Technologies also announced it has raised money in a Series A round, funding that came in at a tune of $15 million.

A U.S. FDA committee gave the nod to continue using Genentech’s checkpoint inhibitor Tecentriq in combination with chemotherapy to treat adults with mTNBC.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564

The final results of the physician-led National Cardiogenic Shock Initiative Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization.

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced financial results for the first quarter of 2021, issued guidance for the second quarter of 2021, and raised guidance for revenue growth and reaffirmed profitability guidance for full-year 2021.

I am very pleased by our first-quarter performance, which is a direct result of our team’s continued perseverance through a difficult operating environment,” commented Curt R.